Cargando…

Effects of sacubitril/valsartan on cardiac reverse remodeling and cardiac resynchronization in patients with acute myocardial infarction

INTRODUCTION: In 2014, the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) has shown that sacubitril/valsartan can reduce the risk of hospitalization and death from cardiovascular causes more effectively than enalapr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Pei, Li, Xiaokang, Wang, Lijin, Wu, Xinlei, Wang, Chiyao, Li, Tian, Wang, Haiyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9880431/ https://www.ncbi.nlm.nih.gov/pubmed/36712243 http://dx.doi.org/10.3389/fcvm.2022.1059420

Ejemplares similares

Efficacy and safety of sacubitril/valsartan vs. valsartan in patients with acute myocardial infarction: A meta-analysis
por: Yang, Pei, et al.
Publicado: (2022)

Molecular mechanisms of sacubitril/valsartan in cardiac remodeling
por: Mustafa, Nor Hidayah, et al.
Publicado: (2022)

Clinical impacts of sacubitril/valsartan on patients eligible for cardiac resynchronization therapy
por: Huang, Hsin‐Ti, et al.
Publicado: (2022)

Effect of sacubitril/valsartan or valsartan on ventricular remodeling and myocardial fibrosis in perimenopausal women with hypertension
por: Chen, Jianshu, et al.
Publicado: (2023)

Evaluation of early left-sided cardiac reverse remodeling under combined therapy of sacubitril-valsartan and spironolactone compared with angiotensin-converting enzyme inhibitors and spironolactone
por: Sacharczuk, Wioletta, et al.
Publicado: (2023)

Cardiac and Vascular Remodeling After 6 Months of Therapy With Sacubitril/Valsartan: Mechanistic Insights From Advanced Echocardiographic Analysis
por: Monosilio, Sara, et al.
Publicado: (2022)

A systematic review and meta-analysis of sacubitril-valsartan in the treatment of ventricular remodeling in patients with heart failure after acute myocardial infarction
por: Zhou, Xiaomin, et al.
Publicado: (2022)

The role of sacubitril/valsartan in the management of cardiac resynchronization therapy non‐responders: a retrospective analysis
por: Chun, Kyeong‐Hyeon, et al.
Publicado: (2020)

Data on effect of Sacubitril/valsartan on cardiac Remodelling in diabetic Cardiomyopathy rats
por: Ai, Jiao, et al.
Publicado: (2021)

Sacubitril/valsartan averts post-myocardial infarction ventricular remodeling and preserves heart function
por: Hajra, Adrija, et al.
Publicado: (2019)

Improvement in quality of life with sacubitril/valsartan in cardiac resynchronization non-responders: The RESINA (RESynchronization plus an Inhibitor of Neprilysin/Angiotensin) registry
por: Campal, José Manuel Rubio, et al.
Publicado: (2021)

Exploration of Mechanisms of Sacubitril/Valsartan in the Treatment of Cardiac Arrhythmias Using a Network Pharmacology Approach
por: Zhou, Yu, et al.
Publicado: (2022)

Effect of Emergency Percutaneous Coronary Intervention Combined with Sacubitril and Valsartan on the Cardiac Prognosis in Patients with Acute Myocardial Infarction
por: Fan, Hai, et al.
Publicado: (2023)

Novel application of drug-coated balloons in coronary heart disease: A narrative review
por: Wang, Lijin, et al.
Publicado: (2023)

Mechanisms of action of sacubitril/valsartan on cardiac remodeling: a systems biology approach
por: Iborra-Egea, Oriol, et al.
Publicado: (2017)

Effect of sacubitril/valsartan on the occurrence of cardiac arrhythmias and the risk of sudden cardiac death in heart failure: A meta-analysis of randomized controlled trials
por: Liu, Xue-Hui, et al.
Publicado: (2022)

Cardiac Reverse Remodelling by 2D and 3D Echocardiography in Heart Failure Patients Treated with Sacubitril/Valsartan
por: Mantegazza, Valentina, et al.
Publicado: (2021)

Transfer RNA-derived small RNAs and their potential roles in the therapeutic heterogeneity of sacubitril/valsartan in heart failure patients after acute myocardial infarction
por: Su, Jia, et al.
Publicado: (2022)

Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats
por: Raj, Pema, et al.
Publicado: (2021)

Effects of sacubitril/valsartan in ESRD patients undergoing hemodialysis with HFpEF
por: Guo, Yanhong, et al.
Publicado: (2022)

The history and mystery of sacubitril/valsartan: From clinical trial to the real world
por: Zhang, Mingsong, et al.
Publicado: (2023)

Improvement of LV Reverse Remodeling Using Dynamic Programming of Fusion-Optimized Atrioventricular Intervals in Cardiac Resynchronization Therapy
por: Wang, Zhongkai, et al.
Publicado: (2021)

The emerging role of sacubitril/valsartan in pulmonary hypertension with heart failure
por: Xu, Yu, et al.
Publicado: (2023)

Clinical efficacy of sacubitril-valsartan combined with acute ST-segment elevation myocardial infarction after reperfusion: A systematic review and meta-analysis
por: Zhang, Dong, et al.
Publicado: (2022)

Sacubitril/valsartan versus valsartan in regressing myocardial fibrosis in hypertension: a prospective, randomized, open-label, blinded endpoint clinical trial protocol
por: Lee, Vivian, et al.
Publicado: (2023)

Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction
por: Moon, Mi‐Gil, et al.
Publicado: (2021)

Does sacubitril/valsartan work in acute myocardial infarction? The PARADISE-AMI study
por: Gatto, Laura
Publicado: (2021)

The Relationship of Myocardial Collagen Metabolism and Reverse Remodeling after Cardiac Resynchronization Therapy
por: Petrovic, Ivana, et al.
Publicado: (2016)

Protection of Sacubitril/Valsartan against Pathological Cardiac Remodeling by Inhibiting the NLRP3 Inflammasome after Relief of Pressure Overload in Mice
por: Li, Xueling, et al.
Publicado: (2020)

Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload
por: Nordén, Einar Sjaastad, et al.
Publicado: (2021)

Effect of Sacubitril-Valsartan on Restoration and Maintenance of Sinus Rhythm in Patients With Persistent Atrial Fibrillation
por: Chen, Qingsong, et al.
Publicado: (2022)

Sacubitril/valsartan attenuates atrial structural remodelling in atrial fibrillation patients
por: Yang, Liu, et al.
Publicado: (2022)

Sacubitril/Valsartan Conundrum
por: Somberg, John
Publicado: (2021)

Effect of Sacubitril/Valsartan on Reducing the Risk of Arrhythmia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Wang, Ruxin, et al.
Publicado: (2022)

Long‐term cardiac reverse remodeling after cardiac resynchronization therapy
por: Alvarez‐Alvarez, Belén, et al.
Publicado: (2021)

Assessing clinical and biomarker characteristics to optimize the benefits of sacubitril/valsartan in heart failure
por: Litwin, Sheldon E., et al.
Publicado: (2022)

Sacubitril/Valsartan Induces Global Cardiac Reverse Remodeling in Long-Lasting Heart Failure with Reduced Ejection Fraction: Standard and Advanced Echocardiographic Evidences
por: Castrichini, Matteo, et al.
Publicado: (2020)

Sex‐based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan
por: Ibrahim, Nasrien E., et al.
Publicado: (2020)

Cardioprotective Effects of LCZ696 (Sacubitril/Valsartan) After Experimental Acute Myocardial Infarction
por: Ishii, Masanobu, et al.
Publicado: (2017)

Protective effect of sacubitril/valsartan in patients with acute myocardial infarction: A meta-analysis
por: Liu, Shanshan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_uv1riisr87eli781ft46f4vvv6